About Us

    Seal Biosciences is a Diagnostic company founded by scientists at UCSF. Our founding technology is based on the discovery of a potential prognostic cancer biomarker – RASGRP1 – which is on the Epidermal Growth Factor pathway and confers a tumor-suppressive effect.

    Our Team


    Dr. Raitt has over 15 years experience in the Biotech industry; Group Leader Oncology/Immunology Target ID & Validation in early drug discovery; Associate Director, Pipeline Sourcing, Nycomed Founder & Principal, Bay Biotech Consulting.

    Patrik has been working for the last +15 years as a CFO and finance advisor for a number of public and privately held companies (VC & PE backed). He has over 20 years of experience in senior leadership roles in Global and International companies. Mr. Jeanmonod has been instrumental in Company M&A, fund raising (equity and debt). Mr. Jeanmonod holds a Master’s Degree in Finance from the University of Geneva.

    Valerie is a corporate and securities attorney who has specific expertise in SEC, NASDAQ, and Sarbanes-Oxley compliance and corporate governance matters and thrives on engineering great deals. She was a corporate and securities attorney at Wilson Sonsini Goodrich & Rosati for 8 years. She served as a law clerk at the U.S. Bankruptcy Court in the Central District of California, and also practiced bankruptcy, corporate and securities law in Columbus, Ohio. She attended UC Irvine and Cornell Law School.

    Medical Team

    Leading authority in the Ras signaling field, Dr. Roose is currently an Associate Professor with tenure at UCSF and runs a research team of 12 people with a focus on understanding the aberrant biochemical signals that drive diseases like leukemia, colorectal cancer, and autoimmunity.

    15+ years as Chief of Surgical Oncology at UCSF; Principal Investigator of two international clinical studies of biomarkers involving >3000 patients with colon cancer.

    Dr. P. Depeille, currently scientist, is working in Dr. Jeroen Roose at UCSF. He has worked in cancer field for 15 years focusing on different aspect for understanding cancer resistance and cellular mechanism. His work led to the discovery of the novel pathway mediating a critical tumor suppressor function on the Ras pathway in colorectal cancer.